Pramodini MedicareShare price, financial results, shareholding and management

NSE Emerge · PRAMODINIDiagnostic imagingListed 19 Aug 2026IPO ₹118Catch them young
Live price on NSE ↗ISIN INE2JG601017 · Lot 1,200 shares · ₹1.25 lakh
₹104.35
+1.20% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹230 cr
Stock P/E
13.5peers 15.4
Book value
₹24
Price to book
4.35
EV / operating profit
-
Market cap to sales
3.71
Returns and growth
ROCE · FY26
41.0%
ROE · FY26
38.6%
ROE, 3-year average
36.2%
Operating margin · FY26
50.0%peers 18.7%
Sales growth, 3 years
26.0%
Profit growth, 3 years
41.5%
Safety
Debt to equity
0.34peers 0.17
Borrowings
₹18 cr
Interest cover
24.0×
Cash from business / op. profit
81%
Debtor days
102
Pledged
0.00%
Ownership and share
Promoter holding
62.64%
Change in promoter holding
-
Shareholders
1,144
High / low since listing
₹137 / ₹97
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Pramodini Medicare share price chart

₹104.35-14.22% since listing

Close on 19 Nov 2026 · +1.21% on the day · Vol 33,600

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
-9.3%
3 months
-11.6%
Since IPO
-11.6%
Traded a day, 20 days
₹0.36 cr
Taken for delivery
80%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+63%+55%
3 years, a year+26%+42%

About Pramodini Medicare: business, products and customers

Pramodini Medicare runs scan and test centres, mostly MRI, CT and X-ray rooms set up inside government and private hospitals, and is paid for each scan it does. Its shares trade on NSE Emerge.

Pramodini Medicare was set up in 2000 and has been led since 2015 by Dr. Chalasani Kuldeep Kumar, a radiologist, and Dr. Chalasani Kavitha. It puts its own scanning machines and technicians into hospitals under agreements with state governments, private hospitals and public sector companies, and also runs its own centres in Vijayawada with a laboratory and a round-the-clock remote reporting desk. Radiology gives almost all its sales; a small lab business and a nuclear medicine service started in FY26 make up the rest.

It works through 16 centres in 14 cities across seven states, with Andhra Pradesh still the largest market. Government hospital partnerships gave about half of FY26 sales, a private hospital partner in Karnataka about a fifth, and a public sector partner in West Bengal and its own centres the rest. In FY26 it more than doubled its machinery, and the number of tests it ran nearly doubled.

Read more about the business

What is new: the shares listed on NSE Emerge in August 2026, and the issue money is meant to pay for equipment at a new centre in Bangalore and at centres in Hubli, Manjeri and Vijayawada. In September 2026 the company took 30% of a new company formed to run a cardiac facility at the Kodagu Institute of Medical Sciences in Karnataka for ten years, a deal it says is with related parties.

From the red herring prospectus (August 2026) and the company's exchange filing of 22 September 2026.

Read the deeper study ↓

In its favour

  • Sales have grown fast: 26% a year over three years.
  • It earns a high return on the money it uses: ROCE 41% in FY26.
  • It brings in more cash than it shows as profit: ₹25 cr against ₹17 cr in FY26.
  • The promoters own a large part of the company: 62.64%.

To watch

  • Spending of ₹45.1 cr of issue money on scanners for Bangalore, Hubli, Manjeri and Vijayawada during FY27 (Red herring prospectus, p.101 and p.102).
  • Start of the Kodagu cardiac facility through Sidheart Advanced Healthcare, 30% held, under a ten-year concession (Exchange filing, 22 Sep 2026, p.2 to p.4).
  • Recovery of the ₹7.3 cr lent to the loss-making associate Vista Pramodini Medicare (Red herring prospectus, p.235 and p.247).
  • Renewal of the fixed-term hospital agreements, which the authorities may put out to tender again (Red herring prospectus, p.35).
  • Its borrowings rose a lot last year: ₹18 cr, from ₹11 cr.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Pramodini Medicare revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew more slowly than sales, so the profit kept from each rupee of sales slipped.

Sales and net profit, every year, ₹ crore
SalesNet profit
020406080Sales, FY22: 25 ₹ cr25Net profit, FY22: 5 ₹ cr5FY22Sales, FY23: 31 ₹ cr31Net profit, FY23: 6 ₹ cr6FY23Sales, FY24: 35 ₹ cr35Net profit, FY24: 7 ₹ cr7FY24Sales, FY25: 38 ₹ cr38Net profit, FY25: 11 ₹ cr11FY25Sales, FY26: 62 ₹ cr62Net profit, FY26: 17 ₹ cr17FY26

Pramodini Medicare profit and loss

Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY22FY23FY24FY25FY26
Sales2531353862
Expenses1316201731
Operating profit1215162131
OPM49.0%49.0%44.0%55.0%50.0%
Other income00101
Interest22211
Depreciation45447
Exceptional and other items1·-1·-1
Profit before tax78101623
Tax rate28.6%25.0%30.0%31.2%26.1%
Net profit5671117
EPS ₹4.924.765.4085.8910.41
Dividend payout0.0%0.0%0.0%0.0%0.0%

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Earnings per share before FY25 is on the share count of that time, before later bonus or share issues, so it does not compare with the years after.

Pramodini Medicare profitability

Margins and returns on capital

Last year the company kept less from each rupee of sales than the year before. It earns a high return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%20%40%60%80%FY22: 49.0%49.0%FY22FY23: 49.0%49.0%FY23FY24: 44.0%44.0%FY24FY25: 55.0%55.0%FY25FY26: 50.0%50.0%FY26
Per cent
FY22FY23FY24FY25FY26
Operating margin49.0%49.0%44.0%55.0%50.0%
Tax rate28.6%25.0%30.0%31.2%26.1%
ROCE·26.3%31.6%41.5%41.0%
ROE·40.0%32.6%37.3%38.6%
Dividend payout0.0%0.0%0.0%0.0%0.0%

Pramodini Medicare debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. It borrowed much more last year. Its loans are smaller than its own money. Last year the business brought in more cash than it showed as profit. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers pay faster than they did in FY24, which frees up the company's money.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
0204060Net worth, FY22: 11 ₹ cr11Borrowings, FY22: 25 ₹ cr25FY22Net worth, FY23: 19 ₹ cr19Borrowings, FY23: 21 ₹ cr21FY23Net worth, FY24: 24 ₹ cr24Borrowings, FY24: 12 ₹ cr12FY24Net worth, FY25: 35 ₹ cr35Borrowings, FY25: 11 ₹ cr11FY25Net worth, FY26: 53 ₹ cr53Borrowings, FY26: 18 ₹ cr18FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
0102030Cash from the business, FY22: 12 ₹ cr12Net profit, FY22: 5 ₹ cr5FY22Cash from the business, FY23: 6 ₹ cr6Net profit, FY23: 6 ₹ cr6FY23Cash from the business, FY24: 10 ₹ cr10Net profit, FY24: 7 ₹ cr7FY24Cash from the business, FY25: 22 ₹ cr22Net profit, FY25: 11 ₹ cr11FY25Cash from the business, FY26: 25 ₹ cr25Net profit, FY26: 17 ₹ cr17FY26

Bars below the line are cash going out.

Pramodini Medicare balance sheet

At each 31 March · ₹ crore

₹ crore
FY22FY23FY24FY25FY26
Equity capital111117
Reserves1018233436
Net worth1119243553
Borrowings2521121118
Other liabilities510131023
Total liabilities4150495694
Fixed assets2622162244
Capital work in progress00000
Investments00000
Other assets1528333450

Pramodini Medicare cash flow

₹ crore

₹ crore
FY22FY23FY24FY25FY26
Cash from operations126102225
Cash from investing-12-1-1-15-31
Cash from financing3-2-11-26
Net cash flow33-250

Working capital

Days

Days
FY22FY23FY24FY25FY26
Debtor days109172186107102
Cash conversion cycle109172186107102
Working capital days-66-361602

Pramodini Medicare peers and competitors

Listed SME companies in the same industry

By sales, Pramodini Medicare is number 9 of the 23 listed SME companies in healthcare services.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Hannah Joseph Hospital23621.5921127.0%0.28
Star Imaging And Path Lab1337.0891937.0%0.18
Nephro Care India14141.988.73.49.4%0.00
Modern Diagnostic & Research Centre9518.183.15.315.4%0.63
Pramodini Medicare23013.5621750.0%0.34
Adeshwar Meditex--56.11.34.9%0.16
ABH Healthcare529.351.65.628.8%3.17
Shanmuga Hospital5713.4454.218.4%0.16
Maitreya Medicare80-44.9-2.5-0.7%0.80
Invicta Diagnostic8417.332.44.930.2%0.07
Nidan Laboratories and Healthcare1912.425.51.519.0%0.16
Median of the 10 others8415.453.94.518.7%0.17

Pramodini Medicare shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Foreign and Indian funds own a noticeable share.

Promoters
62.64%
Foreign investors (FIIs)
2.84%
Indian institutions (DIIs)
8.64%
HNIs (over ₹2 lakh each)
10.82%
Small holders (up to ₹2 lakh)
11.73%
Companies and others
3.33%
Number of shareholders
1,144
1,144 in Aug 26

Pramodini Medicare shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Aug 26
Promoters62.64%
Foreign investors (FIIs)2.84%
Indian institutions (DIIs)8.64%
HNIs (over ₹2 lakh each)10.82%
Small holders (up to ₹2 lakh)11.73%
Companies and others3.33%
Number of shareholders1,144

The named holders are at 18 Aug 2026, each under the group the pattern files them in.

Pramodini Medicare study: the business from its own documents

Read from 1 of the company's own documents

Pramodini Medicare so far

From the company's own record

  1. 19 Aug 2026Listed on NSE Emerge at ₹118
  2. 31 Aug 2026Promoters at 62.64%
  3. 8 Sept 2026Highest close since listing, ₹129.55

Pramodini Medicare key facts from the filings

Each figure with the document it comes from

Centres
16
Diagnostic centres in 14 cities across seven states, including one in Kerala yet to start.Red herring prospectus, p.140 and p.143
Radiology share
97.05%
Share of FY26 sales from scans such as MRI, CT, X-ray and ultrasound.Red herring prospectus, p.29
Tests run
4,74,419
Tests in FY26, up from 2,54,765 in FY25, led by MRI, CT and X-ray.Red herring prospectus, p.141
Largest customer
44.17%
Share of FY26 sales from the single largest customer, down from 63.88% in FY24; the top five gave 64.32%.Red herring prospectus, p.30
Government partnerships
54.19%
Share of FY26 sales from centres in government hospitals, down from 77.22% in FY24 as private and PSU work grew.Red herring prospectus, p.29
Show 5 more facts
Andhra Pradesh
61.90%
Share of FY26 sales from Andhra Pradesh, down from 86.66% in FY24 as Karnataka and West Bengal were added.Red herring prospectus, p.143
Equipment bought
₹29.3 cr
Medical equipment bought in FY26; plant and equipment rose to ₹44.2 cr from ₹21.8 cr.Red herring prospectus, p.317
Issue money for machines
₹45.1 cr
Planned for scanners at a new Bangalore centre and at Hubli, Manjeri and Vijayawada during FY27.Red herring prospectus, p.101 to p.103
Loan to associate
₹7.3 cr
Owed at March 2026 by loss-making associate Vista Pramodini Medicare, up from ₹5.5 cr; the company's unbooked share of its losses was ₹6.1 cr.Red herring prospectus, p.235 and p.247
Cardiac venture
30%
Stake taken in Sidheart Advanced Healthcare, formed to run the Kodagu cardiac facility for ten years; a related party deal.Exchange filing, 22 Sep 2026, p.2 to p.4

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company does not state an order book; its centres run under agreements with hospitals for set terms. The offer document plans to spend the issue money on equipment during FY27, for a new centre in Bangalore, a centre at Manjeri in Kerala that has yet to start, more machines at Hubli and a replacement at Vijayawada. The company also holds a letter of award from the Government of Karnataka for a cardiac facility at Kodagu and a notification of award in Madhya Pradesh.

₹45.1 crIssue money for medical equipmentTo be spent in FY27, offer document
16Diagnostic centresAugust 2026
10 yearsTerm of the Kodagu cardiac concessionExchange filing, 22 Sep 2026

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Pramodini Medicare earns its money by placing scanners inside hospitals and charging for each scan, and once a machine is busy most of the extra income turns into profit.

Its weak spots are a heavy lean on a few government and hospital contracts that must be won and renewed on price, steady spending on costly machines, and money lent to a loss-making associate.

WatchCan it set its own prices?No. Government work is won by tender, usually by the lowest bid, and the company says cutting prices to win can hurt margins.
The evidence. The company says government tenders are typically awarded to the lowest bidder that meets the technical terms, and that all its projects run for a fixed term after which the authority may tender them again.Red herring prospectus, p.35 and p.36
AverageHow strong is it against rivals?It has a doctor-led team, its own machines placed inside hospitals and a record of winning hospital agreements, but larger diagnostic chains compete for the same work.
The evidence. Runs 8 CT, 7 MRI and 20 X-ray machines with 27 CT and MRI technicians across 16 centres. The company says competitors may have greater resources and may offer cheaper services.Red herring prospectus, p.144 and p.43
WatchWho are its customers?Mostly governments and hospitals, with one customer giving close to half the sales, though that share is falling.
The evidence. The largest customer gave 44.17% of FY26 sales, down from 63.88% in FY24, and the top five 64.32%. Government hospital partnerships gave 54.19%.Red herring prospectus, p.29 and p.30
WatchDoes it need a lot of money?Yes. Each new centre needs costly scanners bought up front, and government payers can be slow.
The evidence. Medical equipment of ₹29.3 cr was bought in FY26 and ₹45.1 cr of issue money is set aside for more. Trade receivables were ₹17.4 cr at March 2026.Red herring prospectus, p.317, p.101 and p.29
StrongCan it keep finding new work?It has added new states, partners and services in each of the last few years.
The evidence. Agreements were signed for centres in Karnataka, West Bengal and Haryana in 2025 and Madhya Pradesh in 2026; Andhra Pradesh fell to 61.90% of sales from 86.66% in FY24. Nuclear medicine started in FY26 and a cardiac concession followed in September 2026.Red herring prospectus, p.142 and p.143; Exchange filing, 22 Sep 2026, p.2
AverageDo good and bad years swing a lot?Scans are needed in every season and sales have grown each year, but margins move as new centres open and fill up.
The evidence. EBITDA margin was 44.10% in FY24, 54.83% in FY25 and 49.61% in FY26, while revenue rose each year.Red herring prospectus, p.141

Who runs Pramodini Medicare?

Promoters, directors and officers; tap a name for the background

DCDr. Chalasani Kuldeep KumarPromoter, Chairman and Managing Director · holds 35.71%

MBBS from Nagpur University (2002) and MD in radio-diagnosis from Rajiv Gandhi University of Health Sciences, Karnataka (2006). Earlier Chief Resident at Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, and Associate Professor at Dr Pinnamaneni Siddhartha Institute of Medical Sciences. More than 20 years in medicine and radio-diagnosis; with the company since 2015 and in charge of its overall management. FY26 pay was ₹0.60 cr.

Red herring prospectus, p.181, p.183 and p.240
DCDr. Chalasani KavithaPromoter and Non-Executive Director · holds 6.77%

MBBS and MS in obstetrics and gynaecology from Kasturba Medical College, Manipal, DNB in the same field and a fellowship in gynaecological endoscopy, with more than 20 years in the field. With the company since 2015; works on partnerships and new business. The prospectus states Dr. Chalasani Kavitha is the wife of Dr. Chalasani Kuldeep Kumar.

Red herring prospectus, p.181, p.183, p.184 and p.185
SRSri Ram Medicare Private LimitedPromoter company · holds 20.16%

Incorporated in Vijayawada in March 2012; owned and directed by Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha and Ms. Chalasani Lalithakumari.

Red herring prospectus, p.198
MCMs. Chalasani Durga AashrithaPromoter and Non-Executive Director

A medical student in the third professional MBBS course at Dr. Pinnamaneni Siddhartha Institute of Medical Sciences; on the board since September 2025. The prospectus states Ms. Chalasani Durga Aashritha is the daughter of Dr. Chalasani Kuldeep Kumar and Dr. Chalasani Kavitha.

Red herring prospectus, p.182, p.184 and p.185
MCMs. Chalasani LalithakumariPromoter

MBBS from Andhra University (1974) and a diploma in gynaecology and obstetrics from Nagarjuna University (1978); associated with Sri Ram Medicare Private Limited since 2012. Not a director of the company.

Red herring prospectus, p.198
MRMr. Rajkamal KonaChief Financial Officer

M.Com from Acharya Nagarjuna University, with 12 years in accounts and finance at firms including National Small Industries Corporation and Sarvani Industries. Chief Financial Officer since January 2026.

Red herring prospectus, p.194
MPMr. Potturi Srinivasa Naga Venkata Krishna KishoreChief Operating Officer

BCA from Nagarjuna University and a master's in hospital management from Osmania University, with more than 18 years in hospital administration at NRI Academy of Sciences, NRI Medical College and GMR Varalakshmi CARE Hospital. With the company since September 2021.

Red herring prospectus, p.194
DEDr. Eshwar Chandra NanduryIndependent Director

MBBS from Kakatiya University and MD in radiodiagnosis from PGIMER, Chandigarh, with over 31 years in radiology; head of radiology and senior consultant at Yashoda Hospitals. On the board since January 2026.

Red herring prospectus, p.182, p.183 and p.184
MMMr. Manas DashIndependent Director

B.Com (Hons.) and LL.B. from Utkal University and a fellow chartered accountant, practising since 2003 with over 22 years of experience. On the board since January 2026.

Red herring prospectus, p.183 and p.184

Pramodini Medicare latest news and announcements

Announcements · Documents · Corporate actions

Pramodini Medicare annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Offer document

Pramodini Medicare share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Pramodini Medicare's data · 7

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (2,20,45,595 shares).
  • !The FY26 results imply 1,70,00,000 shares at face value ₹10, which disagrees with the shareholding pattern; the pattern is used.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • !Earnings per share changes basis between FY24 (₹5.40) and FY25 (₹85.89) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY22 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Pramodini Medicare

What does Pramodini Medicare do?

Pramodini Medicare runs scan and test centres, mostly MRI, CT and X-ray rooms set up inside government and private hospitals, and is paid for each scan it does. Its shares trade on NSE Emerge.

What is the share price of Pramodini Medicare?

₹104 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Pramodini Medicare?

₹230 cr at the close on 19 Nov 2026, on 2,20,45,595 shares.

What is the P/E of Pramodini Medicare?

13.5 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Pramodini Medicare's revenue and profit?

Revenue ₹62 cr and profit after tax ₹17 cr in FY26.

Who are the promoters of Pramodini Medicare?

Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Sri Ram Medicare Private Limited, Ms. Chalasani Durga Aashritha, Ms. Chalasani Lalithakumari; promoters held 62.64% at 31 Aug 2026.

What was the IPO price of Pramodini Medicare?

₹118 a share; it listed on 19 Aug 2026.

More SME companies like Pramodini Medicare

Other listed SME companies in healthcare services, the closest in size first, each read from its own documents.

Every listed SME company in Healthcare Services → · SME companies listed in 2026 →

Built from 1 offer document, 10 exchange announcements, 1 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.